On October 30, 2023 Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, reported that management will present at the following investor conferences in November (Press release, Immunocore, OCT 30, 2023, View Source [SID1234636443]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TD Cowen Fall Oncology Innovation Summit: Insights for SITC (Free SITC Whitepaper) and ASH (Free ASH Whitepaper)
Fireside Chat: Friday, November 3, 2023, at 2:20 p.m. EDT
Truist Securities BioPharma Symposium
1×1 and small group meetings: Wednesday, November 8, 2023
Jefferies London Healthcare Conference
Fireside Chat: Tuesday, November 14, 2023, at 2:30 p.m. GMT
3rd Annual BTIG Ophthalmology Day
Fireside Chat: Monday, November 27, 2023, at 10:30 a.m. EST

Where relevant, the presentations will be webcast live and can be accessed by visiting ‘Events’, under ‘News & Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the events, a replay of the presentations will be made available for a limited time.